Lipid disulfide prodrugs and uses related thereto

US11090316B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11090316-B2
Application numberUS-202016899913-A
CountryUS
Kind codeB2
Filing dateJun 12, 2020
Priority dateJul 13, 2017
Publication dateAug 17, 2021
Grant dateAug 17, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of treating a viral infection selected from the group consisting of human immunodeficiency virus (HIV) infection and hepatitis B virus (HBV) infection, comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a salt thereof, wherein, W is Z is O, S, or Se; Y is O, S, or NH; T is an aryl or alkyl linking group; R 1 is a saturated hydrocarbon chain having 6 or more carbon atoms; R 2 is R 1 SST-, hydrogen, alkyl, aryl, phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, naphthyl, or heterocyclyl, wherein R 2 is optionally substituted with one or more, the same or different, R 10 ; R 10 is deuterium, alkyl, alkenyl, alkynyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy, carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl, wherein R 10 is optionally substituted with one or more, the same or different, R 11 ; and R 11 is deuterium, halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methyl sulfinyl, ethylsulfinyl, mesyl, ethyl sulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl. 2. The method of claim 1 , wherein T is a C 2 to C 6 alkyl. 3. The method of claim 1 , wherein Z and Y are each O. 4. The method of claim 1 , wherein R 1 is a C 6 to C 20 saturated hydrocarbon chain. 5. The method of claim 1 , wherein R 2 is R 1 SST-, hydrogen, alkyl, aryl or phenyl. 6. The method of claim 1 , wherein R 2 is hydrogen, methyl, or alkyl. 7. The method of claim 1 , wherein the compound is selected from the following compounds as free acids or salts thereof: 8. The method of claim 1 wherein the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with the viral infection. 9. The method of claim 1 wherein the compound is administered in combination with another antiviral agent. 10. The method of claim 1 , wherein T is —(CH 2 ) n —, wherein n is 2, 3, 4, 5, or 6. 11. The method of claim 10 , wherein n is 2. 12. The method of claim 10 , wherein n is 4 or 5. 13. The method of claim 1 , wherein T is —C 6 H 4 —, —CH 2 —C 6 H 4 —, —C 6 H 4 —CH 2 —, or —CH 2 —C 6 H 4 —CH 2 —. 14. The method of claim 1 , wherein the viral infection is HIV infection. 15. The method of claim 1 , wherein the viral infection is HBV infection.

Assignees

Inventors

Classifications

  • Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title

  • Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • Antivirals · CPC title

  • Purines, e.g. adenine · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11090316B2 cover?
This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are…
Who is the assignee on this patent?
Univ Emory
What technology area does this patent fall under?
Primary CPC classification A61K31/661. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).